Our previous study demonstrated that cytoplasmic GPER in CAFs reduced breast cancer cell drug sensitivities to TAM, Herceptin, or epirubicin by providing tumour cells with lactate and pyruvate.20 The gene discussed is GPER1; the disease is neoplasm.